Medical Oncology Department, Hospital Clínico San Carlos, C/Martín Lagos s/n, 28040, Madrid, Spain.
Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10.
Women with recurrent metastatic breast cancer from a Spanish hospital registry (El Alamo, GEICAM) were analyzed in order to identify the most helpful prognostic factors to predict survival and to ultimately construct a practical prognostic index. The inclusion criteria covered women patients diagnosed with operable invasive breast cancer who had metastatic recurrence between 1990 and 1997 in GEICAM hospitals. Patients with stage IV breast cancer at initial diagnosis or with isolated loco-regional recurrence were excluded from this analysis. Data from 2,322 patients with recurrent breast cancer after primary treatment (surgery, radiation and systemic adjuvant treatment) were used to construct the prognostic index. The prognostic index score for each individual patient was calculated by totalling up the scores of each independent variable. The maximum score obtainable was 26.1. Nine-hundred and sixty-two patients who had complete data for all the variables were used in the computation of the prognostic index score. We were able to stratify them into three prognostic groups based on the prognostic index score: 322 patients in the good risk group (score < or =13.5), 308 patients in the intermediate risk group (score 13.51-15.60) and 332 patients in the poor risk group (score > or =15.61). The median survivals for these groups were 3.69, 2.27 and 1.02 years, respectively (P < 0.0001). In conclusion, risk scores are extraordinarily valuable tools, highly recommendable in the clinical practice.
来自西班牙一家医院注册中心(El Alamo,GEICAM)的复发性转移性乳腺癌女性患者被分析,目的是确定最有助于预测生存的预后因素,并最终构建一个实用的预后指数。纳入标准涵盖了在 GEICAM 医院被诊断为可手术性浸润性乳腺癌且在 1990 年至 1997 年间发生转移性复发的女性患者。本分析排除了初诊时即患有 IV 期乳腺癌或仅发生局部区域性复发的患者。使用 2322 例在原发性治疗(手术、放疗和全身辅助治疗)后发生复发性乳腺癌患者的数据构建了预后指数。通过累加每个独立变量的得分来计算每个患者的预后指数得分。患者的最高得分为 26.1 分。962 例患者的所有变量数据完整,用于计算预后指数得分。我们能够根据预后指数得分将他们分为三个预后组:322 例患者为低危组(得分<或=13.5),308 例患者为中危组(得分 13.51-15.60),332 例患者为高危组(得分>或=15.61)。这些组的中位生存时间分别为 3.69、2.27 和 1.02 年(P<0.0001)。总之,风险评分是非常有价值的工具,在临床实践中强烈推荐使用。